Verbindungen und Zusammensetzungen zur Behandlung von Erkrankungen im Zusammenhang mit Sting-Aktivität

Details

Veröffentlichungs-Nr.

EP4768493

Anmeldetag

11. Januar 2017

Veröffentlichung

1. Juli 2026

Rechtsraum

EP

Abstract

This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that are useful, e.g., for treating a condition, disease or disorder in which a decrease or increase in STING activity (e.g., a decrease, e.g., a condition, disease or disorder associated with repressed or impaired STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Anmelder

Firma

Innate Tumor Immunity, Inc.

Land

🇺🇸 USA